Eintrag weiter verarbeiten
Verfügbar über Online-Ressource

Prognostic Impact of Chromosomal Abnormalities In Elderly Patients with Multiple Myeloma Treated with High-Dose Melphalan (MEL140) and Autologous Stem Cell Transplantation

Gespeichert in:

Bibliographische Detailangaben
Zeitschriftentitel: Blood
Personen und Körperschaften: Liebisch, Peter, Straka, Christian, Einsele, Hermann, Hinke, Axel, Sandermann, Andreas, Dohner, Hartmut, Langer, Christian
In: Blood, 116, 2010, 21, S. 1914-1914
Format: E-Article
Sprache: Englisch
veröffentlicht:
American Society of Hematology
Schlagwörter:
Cell Biology
Hematology
Immunology
Biochemistry
author_facet Liebisch, Peter
Straka, Christian
Einsele, Hermann
Hinke, Axel
Sandermann, Andreas
Dohner, Hartmut
Langer, Christian
Liebisch, Peter
Straka, Christian
Einsele, Hermann
Hinke, Axel
Sandermann, Andreas
Dohner, Hartmut
Langer, Christian
author Liebisch, Peter
Straka, Christian
Einsele, Hermann
Hinke, Axel
Sandermann, Andreas
Dohner, Hartmut
Langer, Christian
spellingShingle Liebisch, Peter
Straka, Christian
Einsele, Hermann
Hinke, Axel
Sandermann, Andreas
Dohner, Hartmut
Langer, Christian
Blood
Prognostic Impact of Chromosomal Abnormalities In Elderly Patients with Multiple Myeloma Treated with High-Dose Melphalan (MEL140) and Autologous Stem Cell Transplantation
Cell Biology
Hematology
Immunology
Biochemistry
author_sort liebisch, peter
spelling Liebisch, Peter Straka, Christian Einsele, Hermann Hinke, Axel Sandermann, Andreas Dohner, Hartmut Langer, Christian 0006-4971 1528-0020 American Society of Hematology Cell Biology Hematology Immunology Biochemistry http://dx.doi.org/10.1182/blood.v116.21.1914.1914 <jats:title>Abstract</jats:title> <jats:p>Abstract 1914</jats:p> <jats:sec> <jats:title>Background:</jats:title> <jats:p>Although chromosomal aberrations (CA) have emerged as important outcome predictors in multiple myeloma (MM), the prognostic significance of many recurring genomic changes is still unknown. Moreover, there is only scarce data on the implication of CA in elderly patients (pts.) receiving high-dose chemotherapy (HD-CTX) followed by autologous stem cell transplantation (ASCT).</jats:p> </jats:sec> <jats:sec> <jats:title>Aims:</jats:title> <jats:p>To evaluate the prognostic relevance of recurring CA as detected by cIg-FISH for elderly pts. with MM receiving HD-CTX and ASCT.</jats:p> </jats:sec> <jats:sec> <jats:title>Patients and Methods:</jats:title> <jats:p>Between 05/2001 and 08/2006, 549 pts. 60–70 yrs. of age with newly diagnosed symptomatic MM entered the DSMM II trial of the Deutsche Studiengruppe Multiples Myelom to receive two cycles of HD-CTX (melphalan 140 mg/sqm) followed by ASCT after 3–4 cycles of dexamethason-based induction chemotherapy (IC; arm A1) or no IC (arm A2). cIg-FISH and DNA probes mapping to chromosome bands 1p22, 1q21.2, 6q21, 8p11.2, 9q34, 11q25, 13q14, 14q32, 17p13, and 22q11 were applied to all pts. with sufficient bone marrow specimen at diagnosis. 289 pts. with a median age of 64 yrs. were included in the present analysis.</jats:p> </jats:sec> <jats:sec> <jats:title>Results:</jats:title> <jats:p>After a median follow-up of 82 weeks (w) the following CA were associated with a significantly shorter event-free survival (EFS): 17p13 deletion (17p–; 55 vs. 93 w, p&lt;.0001); translocation t(4;14) (t(4;14); 65 vs. 95 w, p&lt;.001), 1q21.2 gains (+1q21.2; 79 vs. 99 w, p=.0002); 13q14 deletion (13q–; 82 vs. 99 w, p=.03); and 8p11.2 deletion (8p–; 80 vs. 95 w, p=.04). Overall survival (OS) was significantly shorter in pts. with +1q21.2 (148 vs. 231 w, p&lt;.0001); 17p– (118 vs. 219 w, p=.001); and t(4;14) (t(4;14); 195 vs. 223 w, p=.017). In a multivariable analysis t(4;14) (p&lt;.001); 17p– (p=.0089); +1q21.2 (p=.031); and beta-2-microglobulin (p=.033) independently predicted outcome.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion:</jats:title> <jats:p>In this large cohort of uniformly treated elderly pts. with newly diagnosed MM, CA – in particular 17p–, t(4;14), and +1q21.2 – remain strong predictive markers for outcome.</jats:p> <jats:p>Supported by a grant from the Else Kröner-Fresenius-Stiftung to P.L. and H.D.</jats:p> </jats:sec> <jats:sec> <jats:title>Disclosures:</jats:title> <jats:p>No relevant conflicts of interest to declare.</jats:p> </jats:sec> Prognostic Impact of Chromosomal Abnormalities In Elderly Patients with Multiple Myeloma Treated with High-Dose Melphalan (MEL140) and Autologous Stem Cell Transplantation Blood
doi_str_mv 10.1182/blood.v116.21.1914.1914
facet_avail Online
Free
finc_class_facet Chemie und Pharmazie
Biologie
Medizin
format ElectronicArticle
fullrecord blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC52MTE2LjIxLjE5MTQuMTkxNA
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC52MTE2LjIxLjE5MTQuMTkxNA
institution DE-105
DE-14
DE-Ch1
DE-L229
DE-D275
DE-Bn3
DE-Brt1
DE-D161
DE-Zwi2
DE-Gla1
DE-Zi4
DE-15
DE-Pl11
DE-Rs1
imprint American Society of Hematology, 2010
imprint_str_mv American Society of Hematology, 2010
issn 1528-0020
0006-4971
issn_str_mv 1528-0020
0006-4971
language English
mega_collection American Society of Hematology (CrossRef)
match_str liebisch2010prognosticimpactofchromosomalabnormalitiesinelderlypatientswithmultiplemyelomatreatedwithhighdosemelphalanmel140andautologousstemcelltransplantation
publishDateSort 2010
publisher American Society of Hematology
recordtype ai
record_format ai
series Blood
source_id 49
title Prognostic Impact of Chromosomal Abnormalities In Elderly Patients with Multiple Myeloma Treated with High-Dose Melphalan (MEL140) and Autologous Stem Cell Transplantation
title_unstemmed Prognostic Impact of Chromosomal Abnormalities In Elderly Patients with Multiple Myeloma Treated with High-Dose Melphalan (MEL140) and Autologous Stem Cell Transplantation
title_full Prognostic Impact of Chromosomal Abnormalities In Elderly Patients with Multiple Myeloma Treated with High-Dose Melphalan (MEL140) and Autologous Stem Cell Transplantation
title_fullStr Prognostic Impact of Chromosomal Abnormalities In Elderly Patients with Multiple Myeloma Treated with High-Dose Melphalan (MEL140) and Autologous Stem Cell Transplantation
title_full_unstemmed Prognostic Impact of Chromosomal Abnormalities In Elderly Patients with Multiple Myeloma Treated with High-Dose Melphalan (MEL140) and Autologous Stem Cell Transplantation
title_short Prognostic Impact of Chromosomal Abnormalities In Elderly Patients with Multiple Myeloma Treated with High-Dose Melphalan (MEL140) and Autologous Stem Cell Transplantation
title_sort prognostic impact of chromosomal abnormalities in elderly patients with multiple myeloma treated with high-dose melphalan (mel140) and autologous stem cell transplantation
topic Cell Biology
Hematology
Immunology
Biochemistry
url http://dx.doi.org/10.1182/blood.v116.21.1914.1914
publishDate 2010
physical 1914-1914
description <jats:title>Abstract</jats:title> <jats:p>Abstract 1914</jats:p> <jats:sec> <jats:title>Background:</jats:title> <jats:p>Although chromosomal aberrations (CA) have emerged as important outcome predictors in multiple myeloma (MM), the prognostic significance of many recurring genomic changes is still unknown. Moreover, there is only scarce data on the implication of CA in elderly patients (pts.) receiving high-dose chemotherapy (HD-CTX) followed by autologous stem cell transplantation (ASCT).</jats:p> </jats:sec> <jats:sec> <jats:title>Aims:</jats:title> <jats:p>To evaluate the prognostic relevance of recurring CA as detected by cIg-FISH for elderly pts. with MM receiving HD-CTX and ASCT.</jats:p> </jats:sec> <jats:sec> <jats:title>Patients and Methods:</jats:title> <jats:p>Between 05/2001 and 08/2006, 549 pts. 60–70 yrs. of age with newly diagnosed symptomatic MM entered the DSMM II trial of the Deutsche Studiengruppe Multiples Myelom to receive two cycles of HD-CTX (melphalan 140 mg/sqm) followed by ASCT after 3–4 cycles of dexamethason-based induction chemotherapy (IC; arm A1) or no IC (arm A2). cIg-FISH and DNA probes mapping to chromosome bands 1p22, 1q21.2, 6q21, 8p11.2, 9q34, 11q25, 13q14, 14q32, 17p13, and 22q11 were applied to all pts. with sufficient bone marrow specimen at diagnosis. 289 pts. with a median age of 64 yrs. were included in the present analysis.</jats:p> </jats:sec> <jats:sec> <jats:title>Results:</jats:title> <jats:p>After a median follow-up of 82 weeks (w) the following CA were associated with a significantly shorter event-free survival (EFS): 17p13 deletion (17p–; 55 vs. 93 w, p&lt;.0001); translocation t(4;14) (t(4;14); 65 vs. 95 w, p&lt;.001), 1q21.2 gains (+1q21.2; 79 vs. 99 w, p=.0002); 13q14 deletion (13q–; 82 vs. 99 w, p=.03); and 8p11.2 deletion (8p–; 80 vs. 95 w, p=.04). Overall survival (OS) was significantly shorter in pts. with +1q21.2 (148 vs. 231 w, p&lt;.0001); 17p– (118 vs. 219 w, p=.001); and t(4;14) (t(4;14); 195 vs. 223 w, p=.017). In a multivariable analysis t(4;14) (p&lt;.001); 17p– (p=.0089); +1q21.2 (p=.031); and beta-2-microglobulin (p=.033) independently predicted outcome.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion:</jats:title> <jats:p>In this large cohort of uniformly treated elderly pts. with newly diagnosed MM, CA – in particular 17p–, t(4;14), and +1q21.2 – remain strong predictive markers for outcome.</jats:p> <jats:p>Supported by a grant from the Else Kröner-Fresenius-Stiftung to P.L. and H.D.</jats:p> </jats:sec> <jats:sec> <jats:title>Disclosures:</jats:title> <jats:p>No relevant conflicts of interest to declare.</jats:p> </jats:sec>
container_issue 21
container_start_page 1914
container_title Blood
container_volume 116
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
_version_ 1792321563294433286
geogr_code not assigned
last_indexed 2024-03-01T11:03:58.436Z
geogr_code_person not assigned
openURL url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Prognostic+Impact+of+Chromosomal+Abnormalities+In+Elderly+Patients+with+Multiple+Myeloma+Treated+with+High-Dose+Melphalan+%28MEL140%29+and+Autologous+Stem+Cell+Transplantation&rft.date=2010-11-19&genre=article&issn=1528-0020&volume=116&issue=21&spage=1914&epage=1914&pages=1914-1914&jtitle=Blood&atitle=Prognostic+Impact+of+Chromosomal+Abnormalities+In+Elderly+Patients+with+Multiple+Myeloma+Treated+with+High-Dose+Melphalan+%28MEL140%29+and+Autologous+Stem+Cell+Transplantation&aulast=Langer&aufirst=Christian&rft_id=info%3Adoi%2F10.1182%2Fblood.v116.21.1914.1914&rft.language%5B0%5D=eng
SOLR
_version_ 1792321563294433286
author Liebisch, Peter, Straka, Christian, Einsele, Hermann, Hinke, Axel, Sandermann, Andreas, Dohner, Hartmut, Langer, Christian
author_facet Liebisch, Peter, Straka, Christian, Einsele, Hermann, Hinke, Axel, Sandermann, Andreas, Dohner, Hartmut, Langer, Christian, Liebisch, Peter, Straka, Christian, Einsele, Hermann, Hinke, Axel, Sandermann, Andreas, Dohner, Hartmut, Langer, Christian
author_sort liebisch, peter
container_issue 21
container_start_page 1914
container_title Blood
container_volume 116
description <jats:title>Abstract</jats:title> <jats:p>Abstract 1914</jats:p> <jats:sec> <jats:title>Background:</jats:title> <jats:p>Although chromosomal aberrations (CA) have emerged as important outcome predictors in multiple myeloma (MM), the prognostic significance of many recurring genomic changes is still unknown. Moreover, there is only scarce data on the implication of CA in elderly patients (pts.) receiving high-dose chemotherapy (HD-CTX) followed by autologous stem cell transplantation (ASCT).</jats:p> </jats:sec> <jats:sec> <jats:title>Aims:</jats:title> <jats:p>To evaluate the prognostic relevance of recurring CA as detected by cIg-FISH for elderly pts. with MM receiving HD-CTX and ASCT.</jats:p> </jats:sec> <jats:sec> <jats:title>Patients and Methods:</jats:title> <jats:p>Between 05/2001 and 08/2006, 549 pts. 60–70 yrs. of age with newly diagnosed symptomatic MM entered the DSMM II trial of the Deutsche Studiengruppe Multiples Myelom to receive two cycles of HD-CTX (melphalan 140 mg/sqm) followed by ASCT after 3–4 cycles of dexamethason-based induction chemotherapy (IC; arm A1) or no IC (arm A2). cIg-FISH and DNA probes mapping to chromosome bands 1p22, 1q21.2, 6q21, 8p11.2, 9q34, 11q25, 13q14, 14q32, 17p13, and 22q11 were applied to all pts. with sufficient bone marrow specimen at diagnosis. 289 pts. with a median age of 64 yrs. were included in the present analysis.</jats:p> </jats:sec> <jats:sec> <jats:title>Results:</jats:title> <jats:p>After a median follow-up of 82 weeks (w) the following CA were associated with a significantly shorter event-free survival (EFS): 17p13 deletion (17p–; 55 vs. 93 w, p&lt;.0001); translocation t(4;14) (t(4;14); 65 vs. 95 w, p&lt;.001), 1q21.2 gains (+1q21.2; 79 vs. 99 w, p=.0002); 13q14 deletion (13q–; 82 vs. 99 w, p=.03); and 8p11.2 deletion (8p–; 80 vs. 95 w, p=.04). Overall survival (OS) was significantly shorter in pts. with +1q21.2 (148 vs. 231 w, p&lt;.0001); 17p– (118 vs. 219 w, p=.001); and t(4;14) (t(4;14); 195 vs. 223 w, p=.017). In a multivariable analysis t(4;14) (p&lt;.001); 17p– (p=.0089); +1q21.2 (p=.031); and beta-2-microglobulin (p=.033) independently predicted outcome.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion:</jats:title> <jats:p>In this large cohort of uniformly treated elderly pts. with newly diagnosed MM, CA – in particular 17p–, t(4;14), and +1q21.2 – remain strong predictive markers for outcome.</jats:p> <jats:p>Supported by a grant from the Else Kröner-Fresenius-Stiftung to P.L. and H.D.</jats:p> </jats:sec> <jats:sec> <jats:title>Disclosures:</jats:title> <jats:p>No relevant conflicts of interest to declare.</jats:p> </jats:sec>
doi_str_mv 10.1182/blood.v116.21.1914.1914
facet_avail Online, Free
finc_class_facet Chemie und Pharmazie, Biologie, Medizin
format ElectronicArticle
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
geogr_code not assigned
geogr_code_person not assigned
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Mi9ibG9vZC52MTE2LjIxLjE5MTQuMTkxNA
imprint American Society of Hematology, 2010
imprint_str_mv American Society of Hematology, 2010
institution DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-D161, DE-Zwi2, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1
issn 1528-0020, 0006-4971
issn_str_mv 1528-0020, 0006-4971
language English
last_indexed 2024-03-01T11:03:58.436Z
match_str liebisch2010prognosticimpactofchromosomalabnormalitiesinelderlypatientswithmultiplemyelomatreatedwithhighdosemelphalanmel140andautologousstemcelltransplantation
mega_collection American Society of Hematology (CrossRef)
physical 1914-1914
publishDate 2010
publishDateSort 2010
publisher American Society of Hematology
record_format ai
recordtype ai
series Blood
source_id 49
spelling Liebisch, Peter Straka, Christian Einsele, Hermann Hinke, Axel Sandermann, Andreas Dohner, Hartmut Langer, Christian 0006-4971 1528-0020 American Society of Hematology Cell Biology Hematology Immunology Biochemistry http://dx.doi.org/10.1182/blood.v116.21.1914.1914 <jats:title>Abstract</jats:title> <jats:p>Abstract 1914</jats:p> <jats:sec> <jats:title>Background:</jats:title> <jats:p>Although chromosomal aberrations (CA) have emerged as important outcome predictors in multiple myeloma (MM), the prognostic significance of many recurring genomic changes is still unknown. Moreover, there is only scarce data on the implication of CA in elderly patients (pts.) receiving high-dose chemotherapy (HD-CTX) followed by autologous stem cell transplantation (ASCT).</jats:p> </jats:sec> <jats:sec> <jats:title>Aims:</jats:title> <jats:p>To evaluate the prognostic relevance of recurring CA as detected by cIg-FISH for elderly pts. with MM receiving HD-CTX and ASCT.</jats:p> </jats:sec> <jats:sec> <jats:title>Patients and Methods:</jats:title> <jats:p>Between 05/2001 and 08/2006, 549 pts. 60–70 yrs. of age with newly diagnosed symptomatic MM entered the DSMM II trial of the Deutsche Studiengruppe Multiples Myelom to receive two cycles of HD-CTX (melphalan 140 mg/sqm) followed by ASCT after 3–4 cycles of dexamethason-based induction chemotherapy (IC; arm A1) or no IC (arm A2). cIg-FISH and DNA probes mapping to chromosome bands 1p22, 1q21.2, 6q21, 8p11.2, 9q34, 11q25, 13q14, 14q32, 17p13, and 22q11 were applied to all pts. with sufficient bone marrow specimen at diagnosis. 289 pts. with a median age of 64 yrs. were included in the present analysis.</jats:p> </jats:sec> <jats:sec> <jats:title>Results:</jats:title> <jats:p>After a median follow-up of 82 weeks (w) the following CA were associated with a significantly shorter event-free survival (EFS): 17p13 deletion (17p–; 55 vs. 93 w, p&lt;.0001); translocation t(4;14) (t(4;14); 65 vs. 95 w, p&lt;.001), 1q21.2 gains (+1q21.2; 79 vs. 99 w, p=.0002); 13q14 deletion (13q–; 82 vs. 99 w, p=.03); and 8p11.2 deletion (8p–; 80 vs. 95 w, p=.04). Overall survival (OS) was significantly shorter in pts. with +1q21.2 (148 vs. 231 w, p&lt;.0001); 17p– (118 vs. 219 w, p=.001); and t(4;14) (t(4;14); 195 vs. 223 w, p=.017). In a multivariable analysis t(4;14) (p&lt;.001); 17p– (p=.0089); +1q21.2 (p=.031); and beta-2-microglobulin (p=.033) independently predicted outcome.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion:</jats:title> <jats:p>In this large cohort of uniformly treated elderly pts. with newly diagnosed MM, CA – in particular 17p–, t(4;14), and +1q21.2 – remain strong predictive markers for outcome.</jats:p> <jats:p>Supported by a grant from the Else Kröner-Fresenius-Stiftung to P.L. and H.D.</jats:p> </jats:sec> <jats:sec> <jats:title>Disclosures:</jats:title> <jats:p>No relevant conflicts of interest to declare.</jats:p> </jats:sec> Prognostic Impact of Chromosomal Abnormalities In Elderly Patients with Multiple Myeloma Treated with High-Dose Melphalan (MEL140) and Autologous Stem Cell Transplantation Blood
spellingShingle Liebisch, Peter, Straka, Christian, Einsele, Hermann, Hinke, Axel, Sandermann, Andreas, Dohner, Hartmut, Langer, Christian, Blood, Prognostic Impact of Chromosomal Abnormalities In Elderly Patients with Multiple Myeloma Treated with High-Dose Melphalan (MEL140) and Autologous Stem Cell Transplantation, Cell Biology, Hematology, Immunology, Biochemistry
title Prognostic Impact of Chromosomal Abnormalities In Elderly Patients with Multiple Myeloma Treated with High-Dose Melphalan (MEL140) and Autologous Stem Cell Transplantation
title_full Prognostic Impact of Chromosomal Abnormalities In Elderly Patients with Multiple Myeloma Treated with High-Dose Melphalan (MEL140) and Autologous Stem Cell Transplantation
title_fullStr Prognostic Impact of Chromosomal Abnormalities In Elderly Patients with Multiple Myeloma Treated with High-Dose Melphalan (MEL140) and Autologous Stem Cell Transplantation
title_full_unstemmed Prognostic Impact of Chromosomal Abnormalities In Elderly Patients with Multiple Myeloma Treated with High-Dose Melphalan (MEL140) and Autologous Stem Cell Transplantation
title_short Prognostic Impact of Chromosomal Abnormalities In Elderly Patients with Multiple Myeloma Treated with High-Dose Melphalan (MEL140) and Autologous Stem Cell Transplantation
title_sort prognostic impact of chromosomal abnormalities in elderly patients with multiple myeloma treated with high-dose melphalan (mel140) and autologous stem cell transplantation
title_unstemmed Prognostic Impact of Chromosomal Abnormalities In Elderly Patients with Multiple Myeloma Treated with High-Dose Melphalan (MEL140) and Autologous Stem Cell Transplantation
topic Cell Biology, Hematology, Immunology, Biochemistry
url http://dx.doi.org/10.1182/blood.v116.21.1914.1914